Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

By continuing you agree to the terms and privacy policy.

Welcome — one more step

News Plus opens the cross-newsroom layer — who covered a story, who didn’t, and how each one worded it.

  • Ask Duki without a daily limit — answers from the coverage, with sources
  • Save articles, synced between the web and the app
  • Every Not Everywhere story, no daily limit
  • How each newsroom worded the same event
  • Filing timeline and coverage breakdown
  • The whole archive, searchable
  • Unlimited newsroom, topic and people follows
  • The daily brief by email, in English or Hebrew

Eligible new subscribers get 7 days free, then $34.99 each year. Renews automatically until cancelled. Cancel any time in your account. Subscription terms.

Your subscription also unlocks the app.

Download on theApp StoreGet it onGoogle Play

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Live Terminal
Health · Full coverage

New Pancreatic Cancer Drug Approved by FDA Faces Cost and Accessibility Hurdles

How 2 Israeli newsrooms covered this story — translated into English and compared side by side.

Center 1Unrated 1

By גלי וינרב

First reported by Ynet · Aug 29, 2026

What happened

The FDA has approved Rasonque, a new drug for metastatic pancreatic cancer, offering extended survival but at a high cost. While accessible in Israel via personal import, official market entry and inclusion in the national health basket face significant delays and financial challenges, potentially impacting insurance coverage and patient costs.

  • 01FDA approves Rasonque for metastatic pancreatic cancer, extending survival.
  • 02Drug costs $40,000 monthly, posing significant financial challenges.
  • 03Personal import to Israel possible, but official approval and health basket inclusion are delayed.
  • 04High costs may lead to increased insurance premiums or restricted coverage.
  • 05Company stock surged, with significant market potential estimated.
  • 06Doctors hope for broader application in other RAS-mutated cancers.

Summary translated & synthesized from the sources below by baba. Read each original for the full report.

In this story
People
Donald Trump
OrganizationsFDA, Revolution Medicines, RBC, Merck, Amgen, BMS, Roche, Ichilov Hospital
PlacesU.S., Israel, America, California, Harvard

Full coverage · 2 outlets

The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.

GlobesUnrated · HebrewAug 30, 2026
New Pancreatic Cancer Drug Approved by FDA Faces Cost and Accessibility Hurdles
YnetCenter · HebrewAug 29, 2026
New Pancreatic Cancer Drug's $120,000 Monthly Cost Sparks Patient Despair

Related stories

FDA Approves Breakthrough Drug for Advanced Pancreatic Cancer Extending SurvivalAug 27, 2026Ichilov Launches World-First Clinical Trial for Innovative Pancreatic Cancer TreatmentJul 30, 2026FDA Approves Revtorpyk to Cut Advanced Breast Cancer Progression Risk by 76%Jul 15, 2026CT Review Missed Early Pancreatic Cancer, Patient Dies 18 Months LaterJun 18, 2026New Targeted Therapies Revolutionize Breast Cancer Treatment and Survival in IsraelJul 5, 2026Israeli Family Battles to Secure 14 Million Shekel Drug for Rare Genetic DiseaseJun 28, 2026